emcardioНеотложная кардиология и кардиоваскулярные рискиEmergency Cardiology and Cardiovascular Risks journal2616-633XБелорусский государственный медицинский университет10.51922/2616-633X.2024.8.2.2237emcardio-44Research ArticleОригинальные научные публикацииOriginal Scientific ResearchПодоцин – ранний биомаркер атеросклероза у пациентов с сахарным диабетом 2 типаPodocin as an early biomarker of atherosclerosis in patients with type 2 diabetes mellitusВасильковаО. Н.VasilkovaV.

 Гомель 

 Gomel 

olga.n.vasilkova@gmail.comМохортТ. В.MokhortT.

 Минск 

 Minsk 

ПчелинИ. Ю.PchelinI.

Санкт-Петербург

Saint Petersburg

ПервышинН. А.PervyshinN. A.

 Самара 

Samara

БоровецЯ. А.BorovetsY. A.

 Гомель 

 Gomel 

Гомельский государственный медицинский университетGomel State Medical UniversityБелорусский государственный медицинский университетBelarusian State Medical UniversityСанкт-Петербургский государственный университетSaint Petersburg State UniversityСамарский государственный медицинский университет»Samara State Medical UniversityРеспубликанский научно-практический центр радиационной медицины и экологии человекаRepublican Research Center for Radiation Medicine and Human Ecology202420062025822237–2242Copyright © Василькова О.Н., Мохорт Т.В., Пчелин И.Ю., Первышин Н.А., Боровец Я.А., 20252025Василькова О.Н., Мохорт Т.В., Пчелин И.Ю., Первышин Н.А., Боровец Я.А.Vasilkova V., Mokhort T., Pchelin I., Pervyshin N.A., Borovets Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://emcardio.bsmu.by/jour/article/view/44

Цель исследования. Изучить связь уровней подоцина с атеросклеротическим поражением артерий у пациентов с СД 2 типа.Материалы и методы. В исследование были включены 316 пациентов с СД 2 типа, медиана возраста 66,00 [60,00; 72,00] лет. Проводилось стандартное обследование с оценкой уровней подоцина в моче и ультразвуковое исследование брахиоцефальных артерий с определением толщины комплекса интима-медиа (КИМ).Результаты. Уровни подоцина у пациентов с СД 2 типа были достоверно выше по сравнению с группой контроля (0,615 [0,320; 1,892] против 0,240 [0,140; 0,300] нг/мл, p < 0,001). При проведении корреляционного анализа взаимосвязи подоцина и КИМ ОСА нами была установлена заметной тесноты прямая связь (r = 0,524 для КИМ справа и r = 0,518 для КИМ слева при p < 0,001). Методом бинарной логистической регрессии была определена достоверная связь подоцина с КИМ ОСА, так при увеличении подоцина на 1 нг/мл шансы утолщения КИМ увеличивались в 3,028 раза. Уровень подоцина ≥ 0,806 нг/мл ассоциировался с вероятностью утолщения КИМ с чувствительностью и специфичностью 71,0% и 81,0%, соответственно (AUC ROC 0,778 ± 0,047 с 95% ДИ: 0,686 – 0,871, p < 0,001).Заключение. Подоцин в моче может рассматриваться в качестве раннего маркера атеросклероза у пациентов с СД 2 типа, с чувствительностью 71% и специфичностью 81%.

Introduction. Diabetic nephropathy, on the one hand, is one of the most common causes of end-stage chronic kidney disease in diabetes mellitus (DM), and on the other hand, a risk factor for the development of cardiovascular complications. Microalbumin has traditionally been used in routine practice to assess renal function and cardiovascular risk, however, many markers are now being identified that are associated with renal dysfunction, one of which is podocin. In this regard, it becomes relevant to study podocin in order to predict the risk of developing cardiovascular diseases in diabetes in the future.Purpose. To study the relationship between podocin levels and atherosclerotic arterial lesions in patients with type 2 diabetes.Materials and methods. The study included 316 patients with type 2 diabetes, median age 66.00 [60.00; 72.00] years. The investigation of patients included a standard examination with assessment of podocin levels in urine and ultrasound examination of the brachiocephalic arteries with determination of intima-media thickness (IMT) of the common carotid artery (CCA).Results. Podocin levels in patients with DT2 were significantly higher compared to the control group (0.615 [0.320; 1.892] vs. 0.240 [0.140; 0.300] ng/ml, p < 0.001). When conducting a correlation analysis of the relationship between podocin and IMT CCA, we established a close direct relationship (r = 0.524 for IMT on the right and r = 0.518 for IMT on the left with p < 0.001). Using the binary logistic regression method, a significant association of podocin with IMT CCA was determined, so with an increase in podocin by 1 ng/ml, the chances of IMT thickening increased by 3.028 times. When assessing the probability of IMT thickening using ROC analysis, a cut-off point for podocin of 0.806 ng/mL was obtained, with a sensitivity and pecificity of 71.0% and 81.0%, respectively. The area under the ROC curve was 0.778 ± 0.047 with 95% CI: 0.686 – 0.871, p < 0.001.Conclusion. Urinary podocin in urine can be considered as an early marker of atherosclerosis in patients with type 2 diabetes, with a sensitivity of 71% and specificity of 81%.

сахарный диабетатеросклерозподоцинdiabetes mellitusatherosclerosispodocinReferencesStrain W.D., Paldánius P.M. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol, 2021, vol. 20(1), pp. 120. doi: 10.1186/s12933-021-01307-5.Strain W.D., Paldánius P.M. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol, 2021, vol. 20(1), pp. 120. doi: 10.1186/s12933-021-01307-5.Gimeno-Orna J.A., Molinero-Herguedas E., Sánchez-Vaño R., et al. Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. Diabetes Res Clin Pract, 2006, vol. 74(1), pp. 103-109. doi: 10.1016/j.diabres.2006.03.008.Gimeno-Orna J.A., Molinero-Herguedas E., Sánchez-Vaño R., et al. Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. Diabetes Res Clin Pract, 2006, vol. 74(1), pp. 103-109. doi: 10.1016/j.diabres.2006.03.008.Lamprou S., Koletsos N., Mintziori G. et al. Microvascular and Endothelial Dysfunction in Prediabetes. Life (Basel), 2023, vol. 13(3), pp. 644. doi: 10.3390/life13030644.Lamprou S., Koletsos N., Mintziori G. et al. Microvascular and Endothelial Dysfunction in Prediabetes. Life (Basel), 2023, vol. 13(3), pp. 644. doi: 10.3390/life13030644.Nonterah E.A., Boateng D., Crowther N.J., et al. Carotid Atherosclerosis, Microalbuminuria, and Estimated 10-Year Atherosclerotic Cardiovascular Disease Risk in Sub-Saharan Africa. JAMA Netw Open, 2022, vol. 5(4), pp. e227559. doi: 10.1001/jamanetworkopen.2022.7559.Nonterah E.A., Boateng D., Crowther N.J., et al. Carotid Atherosclerosis, Microalbuminuria, and Estimated 10-Year Atherosclerotic Cardiovascular Disease Risk in Sub-Saharan Africa. JAMA Netw Open, 2022, vol. 5(4), pp. e227559. doi: 10.1001/jamanetworkopen.2022.7559.Vasilkova V., Pchelin I., Bayrasheva V., et al. The role of inflammatory markers and growth factors in progression of chronic kidney disease in patients with diabetes mellitus. J Renal Inj Prev, 2024, vol. x(x), pp. e32188. doi: 10.34172/jrip.2023.31188.Vasilkova V., Pchelin I., Bayrasheva V., et al. The role of inflammatory markers and growth factors in progression of chronic kidney disease in patients with diabetes mellitus. J Renal Inj Prev, 2024, vol. x(x), pp. e32188. doi: 10.34172/jrip.2023.31188.Butt L., Unnersjö-Jess D., Reilly D., et al. In vivo characterization of a podocyte-expressed short podocin isoform. BMC Nephro, 2023, vol. 24(1), pp.378. doi: 10.1186/s12882-023-03420-x.Butt L., Unnersjö-Jess D., Reilly D., et al. In vivo characterization of a podocyte-expressed short podocin isoform. BMC Nephro, 2023, vol. 24(1), pp.378. doi: 10.1186/s12882-023-03420-x.Eid A.A., Habib R.H., Chehab O., et al. Podocyturia: an earlier biomarker of cardiovascular outcomes. Sci Rep, 2022, vol. 12(1), pp. 21563. doi: 10.1038/s41598-022-26162-6.Eid A.A., Habib R.H., Chehab O., et al. Podocyturia: an earlier biomarker of cardiovascular outcomes. Sci Rep, 2022, vol. 12(1), pp. 21563. doi: 10.1038/s41598-022-26162-6.Granier C., Makni K., Molina L. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant, 2008, vol. 23, pp. 792-799. doi: 10.1093/ndt/gfm834.Granier C., Makni K., Molina L. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant, 2008, vol. 23, pp. 792-799. doi: 10.1093/ndt/gfm834.Bobkova I.N., Shchukina A.A., Shestakova M.V. Clinical significance of determining urinary excretion of nephrin and podocin in patients with diabetes mellitus. Clinical pharmacology and therapy, 2017, vol. 26(5), pp. 31-36.Bobkova I.N., Shchukina A.A., Shestakova M.V. Clinical significance of determining urinary excretion of nephrin and podocin in patients with diabetes mellitus. Clinical pharmacology and therapy, 2017, vol. 26(5), pp. 31-36.Bobkova I.N., Shestakova M.V., Schukina A.A Diabetic nephropathy - focus on podocytes damage. Nephrology (saint-petersburg), 2015, vol. 2(19), pp. 33-44.Bobkova I.N., Shestakova M.V., Schukina A.A Diabetic nephropathy - focus on podocytes damage. Nephrology (saint-petersburg), 2015, vol. 2(19), pp. 33-44.Reddy G.R., Kotlyarevska K., Ransom R.F. The podocyte and diabetes mellitus: is the podocyte key to the origins of diabetic nephropathy? Сurr Opin Nephrol Hypertens, 2008, vol. 17, pp. 32-36. doi: 10.1097/MNH.0b013e3282f2904d.Reddy G.R., Kotlyarevska K., Ransom R.F. The podocyte and diabetes mellitus: is the podocyte key to the origins of diabetic nephropathy? Сurr Opin Nephrol Hypertens, 2008, vol. 17, pp. 32-36. doi: 10.1097/MNH.0b013e3282f2904d.Kriz, W. Podocytes as a target for treatment with ACE inhibitors and/or angiotensin-receptor blockers. Kidney Int, 2004, vol. 65, pp. 333-334. doi. 10.1111/ j.1523-1755.2004.00421.x.Kriz, W. Podocytes as a target for treatment with ACE inhibitors and/or angiotensin-receptor blockers. Kidney Int, 2004, vol. 65, pp. 333-334. doi. 10.1111/ j.1523-1755.2004.00421.x.Toto R.D., Rinner S., Ram C.V. ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents? Postgrad Med, 2004, vol. 116(2), pp. 11-6,19-22,48. doi: 10.3810/pgm.2004.08.1567.Toto R.D., Rinner S., Ram C.V. ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents? Postgrad Med, 2004, vol. 116(2), pp. 11-6,19-22,48. doi: 10.3810/pgm.2004.08.1567.

The authors declare that there are no conflicts of interest present.